Mary Crowell, MD
Endocrinology, Diabetes & Metabolism · Hyannis, MANPI 1003854365
Payments from drug & device makers
Across 220 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$781
- Abbott$567
- Lilly USA, LLC$470
- Novo Nordisk$311
- Boehringer Ingelheim$264
- AstraZeneca$217
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,57696%
- Education$2124%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 41 | $781 |
| Abbott | 11 | $567 |
| Lilly USA, LLC | 24 | $470 |
| Novo Nordisk | 18 | $311 |
| Boehringer Ingelheim | 12 | $264 |
| AstraZeneca | 11 | $217 |
| Medtronic(2 entities) | 10 | $189 |
| E.r. Squibb & Sons, L.L.C. | 9 | $183 |
| GSK | 8 | $172 |
| UCB, Inc. | 9 | $171 |
| Xeris Pharmaceuticals, Inc. | 7 | $153 |
| Johnson & Johnson(2 entities) | 6 | $139 |
| AbbVie | 6 | $122 |
| Tandem Diabetes Care, Inc. | 5 | $119 |
| Sanofi-aventis U.S. LLC | 6 | $111 |
| Fresenius Kabi USA, LLC | 4 | $107 |
| Dexcom, Inc. | 4 | $95 |
| Vertex | 2 | $57 |
| Bayer | 3 | $56 |
| Corcept Therapeutics | 2 | $50 |
| Bristol Myers Squibb | 2 | $48 |
| Merck | 3 | $46 |
| Sequel Med Tech, LLC | 2 | $44 |
| Radius Health, Inc. | 1 | $34 |
| Recordati_rare_diseases_inc. | 1 | $33 |
| Sandoz | 1 | $29 |
| Shire North American Group Inc | 2 | $28 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Insulet Corporation | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Sanofi | 1 | $20 |
| Valeritas, Inc. | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Sobi, Inc | 1 | $16 |
| Cequr Corporation | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,788 in reported general payments places this provider in the 65th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 162 | $243,015 |
| TrulicityDulaglutide | 193 | $233,447 |
| MounjaroTirzepatide | 117 | $140,441 |
| JardianceEmpagliflozin | 91 | $130,834 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $84,127 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $56,841 |
| TymlosAbaloparatide | 18 | $48,314 |
| JanuviaSitagliptin Phosphate | 38 | $45,157 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $32,455 |
| FarxigaDapagliflozin Propanediol | 23 | $28,719 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 22 | $28,034 |
| SynthroidLevothyroxine Sodium | 237 | $26,327 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $25,074 |
| Cinacalcet Hcl | 11 | $17,326 |
| TirosintLevothyroxine Sodium | 79 | $15,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $470 | $382,287338 claims |
| Novo NordiskOzempic, Novolog | $311 | $247,460179 claims |
| Boehringer IngelheimJardiance | $264 | $130,83491 claims |
| Radius Health, Inc.Tymlos | $34 | $48,31418 claims |
| MerckJanuvia | $46 | $45,15738 claims |
| AbbVieSynthroid, Armour Thyroid | $122 | $31,692267 claims |
| AstraZenecaFarxiga | $217 | $28,71923 claims |
| PfizerLevoxyl | $14 | $3,17163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Hyannis
- David NathanBoston$9M
- Vanita ArodaBoston$4.2M
- George KingBoston$3.7M
- Karen MillerBoston$2.9M
- Steven GrinspoonBoston$2.7M
- Jason GagliaBoston$2.5M
- Tamer YacoubFall River$1.4M
- Elaine YuBoston$1.3M
- Osama HamdyBoston$1.1M
- Steven RussellBoston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.